{"id":"W4408236029","doi":"10.1038/s41591-025-03575-0","title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Randomized controlled trial; Biomarker; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002267114,0.0009033826,0.001133153,0.0002097716,0.0002354885,0.0007782999,0.0004175987,0.0007406584,0.001565226],"category_scores_gemma":[0.001516663,0.0002559222,0.001584751,0.0002957061,0.0005396267,0.0004834196,0.0002613323,0.001506158,0.0002586954],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007617242,"about_ca_system_score_gemma":0.001078309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000508813,"about_ca_topic_score_gemma":0.001722093,"domain_scores_codex":[0.9993486,0.0004542634,0.00002604935,0.00007113485,0.00003537357,0.00006458385],"domain_scores_gemma":[0.9993058,0.0002219783,0.000170973,0.00006355954,0.00004202468,0.000195609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9451334,0.005584636,0.003739165,0.0005047033,0.002142907,0.00007068656,0.00009919251,0.001097478,0.01451853,0.0001869066,0.000891863,0.02603055],"study_design_scores_gemma":[0.8373298,0.1416526,0.01212639,0.00005816819,0.002158383,0.00009809552,0.00004024438,0.001549118,0.003058658,0.0004516436,0.001448968,0.00002784711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950358,0.00197393,0.0003094575,0.0003332512,0.00007194941,0.001101617,0.0004705865,0.00003658968,0.0006667887],"genre_scores_gemma":[0.9936298,0.0009201116,0.00144219,0.0005212745,0.00007989827,0.001678133,0.0009015082,0.00001944372,0.0008077068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002267114,"threshold_uncertainty_score":0.01198977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03941585590825022,"score_gpt":0.4172139224332038,"score_spread":0.3777980665249536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}